Suppr超能文献

万古霉素诱导的老年中国患者急性肾损伤:一项单中心横断面研究。

Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.

机构信息

Department of Pharmacy, Zhongshan Hospital FuDan University, Shanghai, China.

出版信息

Br J Clin Pharmacol. 2018 Aug;84(8):1706-1718. doi: 10.1111/bcp.13594. Epub 2018 May 24.

Abstract

AIMS

The objective of the present study was to investigate the current situation concerning, and risk factors for, vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assess outcomes and risk factors in patients who have developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of this condition in these patients.

METHOD

We retrospectively identified elderly older inpatients who had received four or more doses of VAN treatment. We compared patients with VI-AKI with those who received VAN treatment and had not developed AKI (NO-AKI). We defined VI-AKI as developing AKI during VAN therapy or within 3 days after withdrawal of VAN.

RESULTS

A total of 647 out of 862 elderly inpatients were included in the study. Among those excluded, in 89.3% of cases (192/215) this was because of lack of data on serum creatinine (SCr). Among included patients, 32.5% (210/647) of patients received therapeutic drug monitoring (TDM) during VAN therapy. In 66.9% of cases (424/634), there was insufficient TDM, and in 3.9% (25/634) this was appropriate. A total of 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricaemia [odds ratio (OR) = 3.045; P = 0.000)], mechanical ventilation (OR = 1.906; P = 0.022) and concomitant vasopressor therapy (OR = 1.919; P = 0.027) were independent risk factors for VI-AKI; higher serum albumin (OR = 0.885; P = 0.000) was determined to be an independent protective factor for VI-AKI.

CONCLUSIONS

For the elderly Chinese patients treated with VAN, there was insufficient monitoring of SCr, too little use of VAN TDM, and lower rate of patients whose VAN though serum concentrations were not obtained at the correct time. We recommend that hospital managers increase investment in clinical pharmacists, to strengthen professional management. Patients with concomitant hyperuricaemia and on mechanical ventilation and vasopressor therapy should be paid more attention, and a higher serum albumin was determined to be an independent protective factor for VI-AKI.

摘要

目的

本研究旨在探讨中国老年患者万古霉素(VAN)诱导的急性肾损伤(VI-AKI)的现状和危险因素,评估发生 VI-AKI 患者的结局和危险因素,为改善此类患者的预防和治疗提供建议。

方法

我们回顾性纳入接受 4 剂或以上 VAN 治疗的老年住院患者。我们将 VI-AKI 患者与接受 VAN 治疗且未发生 AKI(NO-AKI)的患者进行比较。我们将 VI-AKI 定义为在 VAN 治疗期间或 VAN 停药后 3 天内发生 AKI。

结果

共纳入 862 例老年住院患者中的 647 例,其中 89.3%(192/215)因缺乏血清肌酐(SCr)数据而被排除。在纳入的患者中,32.5%(210/647)在 VAN 治疗期间接受了治疗药物监测(TDM)。在 66.9%(424/634)的病例中,TDM 不足,3.9%(25/634)的 TDM 是合适的。共有 102 例患者确诊为 VI-AKI,发生率为 15.8%(102/647)。多因素 logistic 回归分析显示,高尿酸血症(OR=3.045;P=0.000)、机械通气(OR=1.906;P=0.022)和同时使用血管加压药(OR=1.919;P=0.027)是 VI-AKI 的独立危险因素;血清白蛋白较高(OR=0.885;P=0.000)是 VI-AKI 的独立保护因素。

结论

对于接受 VAN 治疗的中国老年患者,SCr 监测不足,VAN TDM 应用较少,未能在正确时间获得 VAN 血药浓度的患者比例较低。我们建议医院管理者增加对临床药师的投入,加强专业管理。对于同时伴有高尿酸血症、机械通气和血管加压药治疗的患者应给予更多关注,较高的血清白蛋白是 VI-AKI 的独立保护因素。

相似文献

1
Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.
Br J Clin Pharmacol. 2018 Aug;84(8):1706-1718. doi: 10.1111/bcp.13594. Epub 2018 May 24.
2
Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China.
PLoS One. 2017 Apr 20;12(4):e0175688. doi: 10.1371/journal.pone.0175688. eCollection 2017.
5
Evaluation of Intra-Operative Topical Vancomycin and the Incidence of Acute Kidney Injury.
Surg Infect (Larchmt). 2021 Oct;22(8):810-817. doi: 10.1089/sur.2020.303. Epub 2021 Feb 10.
7
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Int J Antimicrob Agents. 2018 Aug;52(2):180-184. doi: 10.1016/j.ijantimicag.2018.03.024. Epub 2018 Apr 9.
8
Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
Intern Emerg Med. 2021 Jun;16(4):975-979. doi: 10.1007/s11739-020-02624-5. Epub 2021 Jan 13.

引用本文的文献

2
Vancomycin associated acute kidney injury in patients with infectious endocarditis: a large retrospective cohort study.
Front Pharmacol. 2023 Nov 13;14:1260802. doi: 10.3389/fphar.2023.1260802. eCollection 2023.
3
Risk factors for acute kidney injury associated with intravenous vancomycin in neurosurgical inpatients: a retrospective study.
Eur J Clin Pharmacol. 2024 Jan;80(1):65-73. doi: 10.1007/s00228-023-03581-6. Epub 2023 Oct 27.
7
Vancomycin Associated Acute Kidney Injury: A Longitudinal Study in China.
Front Pharmacol. 2021 Mar 8;12:632107. doi: 10.3389/fphar.2021.632107. eCollection 2021.

本文引用的文献

1
Acute Kidney Injury in Elderly Population: A Prospective Observational Study.
Nephron. 2018;138(2):104-112. doi: 10.1159/000481181. Epub 2017 Nov 23.
4
The Effect of Treatment on Short-Term Outcomes in Elderly Patients with Acute Kidney Injury.
Open Access Maced J Med Sci. 2017 Aug 9;5(5):635-640. doi: 10.3889/oamjms.2017.148. eCollection 2017 Aug 15.
5
Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein.
Toxicol Lett. 2017 Aug 5;277:9-17. doi: 10.1016/j.toxlet.2017.05.023. Epub 2017 May 23.
6
The Nephrotoxicity of Vancomycin.
Clin Pharmacol Ther. 2017 Sep;102(3):459-469. doi: 10.1002/cpt.726. Epub 2017 Jun 5.
7
Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China.
PLoS One. 2017 Apr 20;12(4):e0175688. doi: 10.1371/journal.pone.0175688. eCollection 2017.
10
Impact of a Pharmacist-Initiated Vancomycin Monitoring Program.
Consult Pharm. 2016 Sep;31(9):505-10. doi: 10.4140/TCP.n.2016.505.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验